Midlife diagnosis of Refsum Disease in siblings with Retinitis Pigmentosa – the footprint is the clue: a case report
© Jayaram and Downes; licensee BioMed Central Ltd. 2008
Received: 16 June 2007
Accepted: 12 March 2008
Published: 12 March 2008
Refsum disease is a potentially lethal and disabling condition associated with retinitis pigmentosa in which early treatment can prevent some of the systemic manifestations.
We present the cases of two brothers with a diagnosis of retinitis pigmentosa from childhood in whom Refsum disease was subsequently diagnosed midlife, after routine enquiry into hand and feet abnormalities. Subsequent treatment through dietary modification stabilised visual impairment and has prevented development of neurological complications to date.
It is therefore important to consider the diagnosis of Refsum disease in any patient with autosomal recessive or simplex retinitis pigmentosa, and to enquire about the presence of "unusual" feet or hands in such patients.
Refsum disease is a potentially lethal and disabling condition associated with retinitis pigmentosa in which early treatment can prevent some of the systemic manifestations. We present the cases of two brothers with a diagnosis of retinitis pigmentosa from childhood in whom Refsum disease was subsequently diagnosed midlife, after routine enquiry into hand and feet abnormalities. Subsequent treatment through dietary modification stabilised visual impairment and has prevented development of neurological complications to date.
Both brothers started a special RD diet and serum phytanic acid levels have been reduced significantly as a consequence. Although their visual impairment is unchanged, the younger sibling reported an improvement in his sense of taste and smell and neither sibling has shown any sign of neurological complications to date.
RP comprises a group of genetic conditions affecting 1 in 3000 to 4000 in the population, leading to progressive photoreceptor degeneration and visual loss . RP is also seen as part of several syndromic conditions, some with severe neurological features. RD, Bassen-Kornsweig syndrome, vitamin E deficiency, and gyrate atrophy are examples of conditions within this group that are amenable to dietary modification that can influence the course of disease.
RD is an autosomal recessive disease with an incidence thought to be less than 1:250000, although the exact incidence and prevalence of the disorder in the general population is not known. Dietary phytanic acid (a branched chain fatty acid) accumulates within the body due to an abnormality in a mitochondrial enzyme phytanic acid α-hydroxylase . The condition shows genetic heterogeneity with one locus on chromosome 10  and a second located on chromosome 6 . Phytanic acid accumulates in retinal pigment epithelium and other tissues and causes cellular death through calcium deregulation, free radical formation and apoptosis . Phytanic acid is not only elevated in RD, but also in other peroxisomal disorders. However, these can be distinguished by molecular genetic analysis and clinical phenotype.
The clinical manifestations of RD affect the eyes, nervous system, bones and skin, and most patients are symptomatic before the age of twenty but may present as late as the fifth decade .
Bone spicule retinopathy is a universal and usually early sign in RD. Many patients have noticed night blindness prior to the onset of other symptoms and have constricted visual fields at presentation . Cataract is also a frequent finding in almost 50% of all RD patients .
There is a symmetrical mixed motor and sensory polyneuropathy initially affecting the distal lower limbs, which is chronic and progressive in nature and usually preceded by visual symptoms. Many patients also exhibit cochlear hearing loss. Impaired sense of smell presents early in the disease and is thought to be a universal feature . Cerebellar signs tend to develop later.
Bony abnormalities are seen in over a third of patients and tend to be symmetrical and bilateral in nature . The short tubular bones of the hands and feet are most often affected, in particular the terminal phalanx of the thumb and the fourth metatarsal.
The skin can also be affected with rough scaly thickening seen over the extremities (ichthyosis) . Cardiac abnormalities have also been reported, including cardiomyopathy and conduction disturbances, and may be responsible for causes of sudden death in RD . Reports of cardiac arrhythmias, as well as neurological abnormalities indicate that Refsum patients should therefore be managed by a multidisciplinary team.
Treatment for RD is aimed at lowering the serum levels of phytanic acid. Phytanic acid comes exclusively from exogenous sources and hence dietary restriction of products rich in phytanic acid, such as dairy products and ruminant meats and fat, helps to control serum levels. Restriction of green vegetables has found to be unnecessary as chlorophyll bound phytol has poor bioavailability. Diets which are low in phytanic acid are extremely unpalatable and consequently regimens now include poultry, pork, fruit and vegetables .
Plasmapheresis  or lipopheresis  can be used in the event of acute arrhythmias or extreme weakness. Where dietary control has been inadequate, these treatments have been shown to help improve the clinical picture.
Maintenance of normal serum phytanic acid levels has been associated with improvement in motor nerve conduction velocities, ataxia and stabilisation of the progression of RP . Retinal changes are usually irreversible and hence dietary regimens should be implemented as soon as the diagnosis is made.
RD is a potentially lethal and disabling disease, which is amenable to treatment. Brief neurological screening  and smell testing  of patients with RP have been suggested as possible strategies to identify those who require formal biochemical testing in order to increase the diagnostic yield of RD. Enquiry into the presence of "unusual" feet and hands, as with the cases we have described, may also help distinguish those patients with RD from those with RP alone. However, in view of the severity of the disease, and the fact that it is treatable, phytanic acid testing should be carried out in all cases of autosomal recessive or simplex RP. Early diagnosis of the condition and initiation of an appropriate diet is vital, in order to prevent disease progression and the subsequent development of severe neurological involvement.
Written informed consent was obtained from the patients for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Anne Bolton, Medical Photographer, Oxford Eye Hospital for acquisition of the clinical photographs.
- Haim M, Holm NV, Rosenberg T: Prevalence of retinitis pigmentosa and allied disorders in Denmark. I Main results. Acta Ophthalmol (Copenh). 1992, 70 (2): 178-186.View ArticleGoogle Scholar
- Eldjarn L, Stokke O, Try K: Alpha-oxidation of branched chain fatty acids in man and its failure in patients with Refsum's disease showing phytanic acid accumulation. Scand J Clin Lab Invest. 1966, 18 (6): 694-695. 10.3109/00365516609049057.View ArticlePubMedGoogle Scholar
- Mihalik SJ, Morrell JC, Kim D, Sacksteder KA, Watkins PA, Gould SJ: Identification of PAHX, a Refsum disease gene. Nat Genet. 1997, 17 (2): 185-189. 10.1038/ng1097-185.View ArticlePubMedGoogle Scholar
- van den Brink DM, Brites P, Haasjes J, Wierzbicki AS, Mitchell J, Lambert-Hamill M, de Belleroche J, Jansen GA, Waterham HR, Wanders RJ: Identification of PEX7 as the second gene involved in Refsum disease. Am J Hum Genet. 2003, 72 (2): 471-477. 10.1086/346093.View ArticlePubMedPubMed CentralGoogle Scholar
- Kahlert S, Schonfeld P, Reiser G: The Refsum disease marker phytanic acid, a branched chain fatty acid, affects Ca2+ homeostasis and mitochondria, and reduces cell viability in rat hippocampal astrocytes. Neurobiol Dis. 2005, 18 (1): 110-118. 10.1016/j.nbd.2004.08.010.View ArticlePubMedGoogle Scholar
- Skjeldal OH, Stokke O, Refsum S, Norseth J, Petit H: Clinical and biochemical heterogeneity in conditions with phytanic acid accumulation. J Neurol Sci. 1987, 77 (1): 87-96. 10.1016/0022-510X(87)90209-7.View ArticlePubMedGoogle Scholar
- Gibberd FB, Feher MD, Sidey MC, Wierzbicki AS: Smell testing: an additional tool for identification of adult Refsum's disease. J Neurol Neurosurg Psychiatry. 2004, 75 (9): 1334-1336. 10.1136/jnnp.2003.026690.View ArticlePubMedPubMed CentralGoogle Scholar
- Plant GR, Hansell DM, Gibberd FB, Sidey MC: Skeletal abnormalities in Refsum's disease (heredopathia atactica polyneuritiformis). Br J Radiol. 1990, 63 (751): 537-541.View ArticlePubMedGoogle Scholar
- Ramsay BC, Meeran K, Woodrow D, Judge M, Cream JJ, Clifford Rose F, Gibberd FB: Cutaneous aspects of Refsum's disease. J R Soc Med. 1991, 84 (9): 559-560.PubMedPubMed CentralGoogle Scholar
- Leys D, Petit H, Bonte-Adnet C, Millaire A, Fourrier F, Dubois F, Rosseaux M, Ducloux G: Refsum's disease revealed by cardiac disorders. Lancet. 1989, 1 (8638): 621-10.1016/S0140-6736(89)91654-1.View ArticlePubMedGoogle Scholar
- Brown PJ, Mei G, Gibberd FB: Diet and Refsum's Disease. J Hum Nutr Dietet. 1993, 6: 295-305.View ArticleGoogle Scholar
- Harari D, Gibberd FB, Dick JP, Sidey MC: Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis). J Neurol Neurosurg Psychiatry. 1991, 54 (7): 614-617.View ArticlePubMedPubMed CentralGoogle Scholar
- Gutsche HU, Siegmund JB, Hoppmann I: Lipapheresis: an immunoglobulin-sparing treatment for Refsum's disease. Acta Neurol Scand. 1996, 94 (3): 190-193.View ArticlePubMedGoogle Scholar
- Gibberd FB, Billimoria JD, Goldman JM, Clemens ME, Evans R, Whitelaw MN, Retsas S, Sherratt RM: Heredopathia atactica polyneuritiformis: Refsum's disease. Acta Neurol Scand. 1985, 72 (1): 1-17.View ArticlePubMedGoogle Scholar
- Goldman JM, Clemens ME, Gibberd FB, Billimoria JD: Screening of patients with retinitis pigmentosa for heredopathia atactica polyneuritiformis (Refsum's disease). Br Med J (Clin Res Ed). 1985, 290 (6475): 1109-1110.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.